List of Excipients in API levomilnacipran hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing levomilnacipran hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | ETHYLCELLULOSE | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | FERRIC OXIDE YELLOW | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | FERROSOFERRIC OXIDE | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | HYPROMELLOSE | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | POVIDONE | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | SHELLAC | |
| Allergan Inc | FETZIMA | levomilnacipran hydrochloride | 0456-2220 | SUCROSE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for levomilnacipran hydrochloride
Excipient focus: ETHYLCELLULOSE
levomilnacipran hydrochloride drug variants containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
levomilnacipran hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
levomilnacipran hydrochloride drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
levomilnacipran hydrochloride drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
levomilnacipran hydrochloride drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
levomilnacipran hydrochloride drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
levomilnacipran hydrochloride drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
levomilnacipran hydrochloride drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
levomilnacipran hydrochloride drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIETHYL CITRATE
levomilnacipran hydrochloride drug variants containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | levomilnacipran hydrochloride | 0456-2220 |
| >Company | >Ingredient | >NDC |
levomilnacipran hydrochloride drug variants not containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch